MK-2866 (Ostarine)
em-kay-twenty-eight-sixty-six
Category
Compound type
Phase / Status
Most studied SARM. Phase 3 trials completed for cancer cachexia. Not FDA approved but has the most human data.
Standard Dose
Once daily
Half-life
Plasma elimination
Route(s)
Intramuscular, Subcutaneous or Oral
Research Stage
Research phase not specified; exercise appropriate caution.
Overview
Ostarine is frequently discussed as a 'milder' SARM, but it can still affect hormone levels and may cause side effects such as acne or lipid changes in some people. If you're considering any non-prescribed use, discuss risks with a clinician and treat it as an experimental substance rather than a safe supplement.
Plain-language summary
Ostarine is frequently discussed as a 'milder' SARM, but it can still affect hormone levels and may cause side effects such as acne or lipid changes in some people. If you're considering any non-prescribed use, discuss risks with a clinician and treat it as an experimental substance rather than a safe supplement.
Administration Routes
- Intramuscular
- Subcutaneous
- Oral
Also known as
Mechanisms
Selective androgen receptor modulator (SARM) - partial agonist. Binds androgen receptors selectively in muscle and bone tissue. More selective than the heavy hitters, less suppression.
Detailed mechanism
Selective androgen receptor modulator (SARM) - partial agonist. Binds androgen receptors selectively in muscle and bone tissue. Selectively binds to androgen receptors in muscle and bone tissue while minimizing effects on other organs, promoting anabolic effects with reduced side effects compared to traditional steroids.
Safety
Side effects
- Mild testosterone suppression
- Possible acne
- Possible hair thinning at higher doses
- Headaches
- Back acne reported at higher doses
Reported benefits
- Mild and well-tolerated - best for beginners
- Lean muscle mass preservation during cutting
- Improved joint health and injury recovery
- Enhanced bone density
- Body recomposition (lose fat while gaining muscle simultaneously)
- Minimal suppression at lower doses
Safety profile
Safety profile established through clinical trials. Monitor for potential side effects.
Clinical trials
Phase 3 clinical trials completed, demonstrating efficacy and safety.
Structure
Verified structure
MK-2866 (Ostarine)
Exact 2D structure can be rendered from a PubChem-backed canonical SMILES string.
- Chemical Formula
- C19H14F3N3O3
- Molecular Weight
- 389.33 g/mol
- CAS Number
- 841205-47-8
- InChIKey
- JNGVJMBLXIUVRD-SFHVURJKSA-N
Stack Context
Stacks with
References
- 1View source
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women (Journal of Cachexia, Sarcopenia and Muscle)
2011
- 2View source
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial (Lancet Oncology)
2013
- 3View source
Enobosarm (GTx-024/Ostarine) Phase 3 POWER 1 trial for prevention and treatment of muscle wasting in cancer patients (ClinicalTrials.gov)
2013
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.